<- Go Home
Metacrine, Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is based in San Ramon, California.
Market Cap
$25.5M
Volume
1.7M
Cash and Equivalents
$52.8M
EBITDA
-$36.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$19.5M
Profit Margin
N/A
52 Week High
$0.59
52 Week Low
$0.30
Dividend
N/A
Price / Book Value
0.67
Price / Earnings
-0.60
Price / Tangible Book Value
0.67
Enterprise Value
-$13.5M
Enterprise Value / EBITDA
0.38
Operating Income
-$36.1M
Return on Equity
90.72%
Return on Assets
-36.86
Cash and Short Term Investments
$52.8M
Debt
$13.8M
Equity
$37.1M
Revenue
N/A
Unlevered FCF
-$20.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium